Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors
- 1 July 2001
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (14) , 1057-1071
- https://doi.org/10.1038/sj.gt.3301497
Abstract
The herpes simplex virus type 1 (HSV-1) latency associated promoter (LAP) has been shown to sustain long-term reporter gene expression within sensory neurones. Its activity within the CNS is, however, less well understood. In this study we characterise the activity of the LAP after stereotaxic delivery of recombinant HSV-1-based vectors to the brain. Two classes of vectors were utilised in these studies: (1) a replication-defective vector lacking the glycoprotein H and thymidine kinase genes, designated CS1, and (2) a virus mutant severely impaired for immediate–early (IE) gene expression which lacks functional VP16, ICP4 and ICP0 genes, designated in1388. Both vectors contain the LacZ gene under the control of the LAP. Following delivery of either vector to the striatum, β-gal expression was detected within anatomically related CNS regions distal to the site of injection. At these sites the number of β-gal-positive cells increased with time and remained stable up to 4 weeks p.i. β-Gal expression could not be detected at the site of injection after delivery of CS1 but β-gal expression within neurones located at this site was observed after delivery of in1388, indicating reduced toxicity of this severely disabled virus. Transgene expression decreased dramatically with both vectors at later time-points (>4 weeks after delivery), but PCR analysis demonstrated that viral genomes were stably maintained for up to 180 days following delivery, indicating that the loss of β-gal-positive neurones was not likely to be due to a loss of vector-transduced cells. Moreover, after delivery of an equivalent virus to the rat striatum in situ hybridisation analysis showed a similar decrease in the number of neurones expressing the endogenous LATs with time. These data indicate that although the HSV-1 LAP can drive the expression of foreign genes in a variety of CNS neurones, in these cells there is a slow down-regulation of the viral promoter which eventually results in the loss of detectable transgene expression.Keywords
This publication has 96 references indexed in Scilit:
- Herpes Simplex Virus Type 1 Promoter Activity during Latency Establishment, Maintenance, and Reactivation in Primary Dorsal Root Neurons In VitroJournal of Virology, 2001
- Deletion of multiple immediate–early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neuronsGene Therapy, 1998
- Potential and limitations of a γ34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNSGene Therapy, 1998
- The use of herpes simplex virus-based vectors for gene delivery to the nervous systemMolecular Medicine Today, 1997
- A Genetically Inactivated Herpes Simplex Virus Type 2 (HSV-2) Vaccine Provides Effective Protection against Primary and Recurrent HSV-2 DiseaseThe Journal of Infectious Diseases, 1997
- Expression of the lacZ Reporter Gene in the Rat Basal Forebrain, Hippocampus, and Nigrostriatal Pathway Using a Nonreplicating Herpes Simplex VectorExperimental Neurology, 1996
- Gene Transfer to Neurons Using Herpes Simplex Virus-Based VectorsAnnual Review of Neuroscience, 1996
- Construction and Characterization of Herpes Simplex Virus Type 1 Mutants with Defined Lesions in Immediate Early Gene 1Journal of General Virology, 1989
- Detection of HSV-1 genome in central nervous system of latently infected miceNature, 1983
- An Improved Technique for Obtaining Enhanced Infectivity with Herpes Simplex Virus Type 1 DNAJournal of General Virology, 1976